Last updated on February 2018

Open Label Study to Assess Safety PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis


Brief description of study

This is a proof of concept, randomized, open label, 2-arm study of OPRX-106 in subjects with active mild to moderate ulcerative colitis. Eligible subjects will be enrolled and randomized to receive 2 mg or 8 mg of OPRX-106 administered orally, once daily for 8 weeks.

Clinical Study Identifier: NCT02768974

Find a site near you

Start Over